4SC AG (FRA:VSC) FCF Margin %: 0.00% (As of Dec. 2025)


What is 4SC AG FCF Margin %?

4SC AG FRA:VSC FCF Margin % is 0.00% as of Dec. 2025. The stock has 7 warning signs investors should review.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. 4SC AG's Free Cash Flow for the six months ended in Dec. 2025 was €0.00 Mil. 4SC AG's Revenue for the six months ended in Dec. 2025 was €2.55 Mil. Therefore, 4SC AG's FCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, 4SC AG's current FCF Yield % is 0.00%.

The historical rank and industry rank for 4SC AG's FCF Margin % or its related term are showing as below:


During the past 13 years, the highest FCF Margin % of 4SC AG was -85.78%. The lowest was -3141.45%. And the median was -649.81%.

FRA:VSC's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -85.21
* Ranked among companies with meaningful FCF Margin % only.

4SC AG FCF Margin % Related Terms

4SC AG FCF Margin % Historical Data

* Premium members only.

The historical data trend for 4SC AG's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4SC AG FCF Margin % Chart

4SC AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -85.78 -2,152.75 -3,141.45 -2,234.82 0.00

4SC AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:VSC vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, 4SC AG's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

4SC AG FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4SC AG's FCF Margin % distribution charts can be found below:

* The bar in red indicates where 4SC AG's FCF Margin % falls into.


4SC AG FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

4SC AG's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=0/2.587
=0.00 %

4SC AG's FCF Margin for the quarter that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=0/2.548
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
4SC AG (FRA:VSC) has a FCF Margin % of 0.00% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on 4SC AG and its competitors.
Is 4SC AG's FCF Margin % too high?
4SC AG's current FCF Margin % is 0.00%.
How does 4SC AG's FCF Margin % compare to VRTX and REGN?
4SC AG's FCF Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on 4SC AG and its competitors. 4SC AG's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4SC AG stock overvalued right now?
4SC AG (FRA:VSC) has a current FCF Margin % of 0.00%. The stock's GF Value™ is €3.51, compared to a current price of €0.10 — trading 97.2% below its estimated fair value. The current FCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For 4SC AG (FRA:VSC), the current FCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

4SC AG Business Description

Address Fraunhoferstrasse 22, Planegg-Martinsried, DEU, 82152
4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. Its pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development resminostat and Domatinostat. The geographic area of the company is Germany, the EU, and Other countries, and the majority of the revenue comes from Other Countries.